Biohaven signs Ono deal worth up to $100 million
Compartilhar
Biohaven (NYSE:BHVN) entered an exclusive regional licensing agreement with Ono Pharmaceutical covering its IgG degrader portfolio, with near-term payments of up to $100 million.
Biohaven (NYSE:BHVN) entered an exclusive regional licensing agreement with Ono Pharmaceutical covering its IgG degrader portfolio, with near-term payments of up to $100 million.
Biohaven (NYSE:BHVN) and Yale University announced a favorable verdict from a federal jury in the U.S. District Court for the District of Delaware regarding their ongoing litigation against Avilar Therapeutics and RA Capital.
Biohaven (NYSE:BHVN) reported positive preliminary clinical data from its ongoing Phase 1b trials evaluating two novel extracellular protein degraders, hitting key biological markers and clearing a path toward advanced clinical development.
Biohaven (NYSE:BHVN) released new clinical and safety data for opakalim, its selective Kv7.2/7.3 potassium channel activator, showing meaningful reductions in seizure frequency and a highly differentiated central nervous system safety profile across generalized and focal forms of epilepsy.
Biohaven (NYSE:BHVN) signed an exclusive global licensing agreement with SK Biopharmaceuticals for its Kv7 platform valued up to $795 million.
Biohaven (NYSE:BHVN) will present updated Phase 1 data for BHV-1530 at the EORTC-NCI-AACR oncology symposium in November 2026, covering the ongoing BHV1530-101 study.
